trial
as of 2026-07-01NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCTId NCT07114874
at a glance
Phase 3 · Recruiting
Enrollment 600 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2031-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Recruiting
Enrollment
600 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-07-11
Primary completion
2031-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Neurocrine BiosciencesLead Sponsor
Investigators
1
Clinical Development LeadStudy Director
Sites
57 total
Bryant, United StatesLittle Rock, United StatesCerritos, United StatesChino, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLemon Grove, United StatesOceanside, United StatesPico Rivera, United StatesRiverside, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
600
Phase
PHASE3
Primary Completion Date
2031-12
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication
investigator